HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TPN729

a phosphodiesterase type 5 inhibitor; structure in first source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - TPN729: 3
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - TPN729: 3
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - TPN729: 3

Experts

1.	Wang, Zhen: 2 articles (01/2022 - 03/2021)
2.	Zhong, Da-Fang: 2 articles (01/2022 - 03/2021)
3.	Cheng, Huan: 1 article (01/2022)
4.	Diao, Xingxing: 1 article (01/2022)
5.	Fan, Zhen: 1 article (01/2022)
6.	He, Ji-Xiang: 1 article (01/2022)
7.	Wang, Junchen: 1 article (01/2022)
8.	Yan, Shu: 1 article (01/2022)
9.	Yang, Chen: 1 article (01/2022)
10.	Yu, Jinghua: 1 article (01/2022)

Related Diseases

1.

Erectile Dysfunction

01/01/2022 - "TPN729, a novel phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), is in phase II clinical trials in China. "
01/05/2016 - "TPN729 has been reported as a novel phosphodiesterase type 5 (PDE5) inhibitor to treat erectile dysfunction, and is currently being tested in clinical trials. "
03/01/2021 - "TPN729 is a novel phosphodiesterase 5 (PDE5) inhibitor used to treat erectile dysfunction in men. "

Related Drugs and Biologics

1.	Phosphodiesterase 5 Inhibitors
2.	Type 5 Cyclic Nucleotide Phosphodiesterases